---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-009787"
form_type: "8-K"
ticker: "OTLC"
cik: "0000908259"
company_name: "Oncotelic Therapeutics, Inc."
filed_at: "2022-04-13T23:59:59+00:00"
generated_at: "2026-06-26T07:48:13.428152+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Oncotelic forms JV with Dragon Overseas for TGF-beta drug OT-101; Dragon invests ~$27.6M for 55% stake

## Summary
- Oncotelic contributed global, exclusive, perpetual, royalty-free license of OT-101 IP for 45% ownership in JV.
- Dragon Overseas invested ~$27.6M in cash and assets for 55% ownership of the JV.
- JV to develop OT-101 for DIPG, pancreatic cancer, glioblastoma; company retains up to $50M from RPD voucher sale.
- Oncotelic intends to pursue IPO of JV, citing recent successful TGF-beta IPOs.
- JV will assume development costs; Oncotelic will participate via JV equity and voucher proceeds.

## SEC filing metadata
- accession: 0001493152-22-009787
- form_type: 8-K
- ticker: OTLC
- cik: 0000908259
- company_name: Oncotelic Therapeutics, Inc.
- filed_at: 2022-04-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/908259/000149315222009787/0001493152-22-009787-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/908259/000149315222009787/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-009787
- JSON: https://secwatch.observer/filing/0001493152-22-009787.json
- Plain text: https://secwatch.observer/filing/0001493152-22-009787.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.